HRP20100713T1 - Derivati azola i tiazola i njihova upotreba - Google Patents
Derivati azola i tiazola i njihova upotreba Download PDFInfo
- Publication number
- HRP20100713T1 HRP20100713T1 HR20100713T HRP20100713T HRP20100713T1 HR P20100713 T1 HRP20100713 T1 HR P20100713T1 HR 20100713 T HR20100713 T HR 20100713T HR P20100713 T HRP20100713 T HR P20100713T HR P20100713 T1 HRP20100713 T1 HR P20100713T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- alkyl
- compound according
- methyl
- cyclohexyl
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 2
- 150000007979 thiazole derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 27
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 26
- -1 C 1 -C 6 -alkyl Chemical group 0.000 claims abstract 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 16
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 15
- 125000003118 aryl group Chemical group 0.000 claims abstract 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 9
- 125000000461 aryl-fused-heterocycloalkyl group Chemical group 0.000 claims abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
- 239000001257 hydrogen Substances 0.000 claims abstract 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 7
- 125000001374 aryl-fused-cycloalkyl group Chemical group 0.000 claims abstract 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 5
- 201000010099 disease Diseases 0.000 claims abstract 5
- 125000004450 alkenylene group Chemical group 0.000 claims abstract 4
- 125000002947 alkylene group Chemical group 0.000 claims abstract 4
- 125000004419 alkynylene group Chemical group 0.000 claims abstract 4
- 125000004429 atom Chemical group 0.000 claims abstract 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 3
- 239000001301 oxygen Substances 0.000 claims abstract 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 3
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 3
- 150000002825 nitriles Chemical class 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 19
- 125000006413 ring segment Chemical group 0.000 claims 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000001544 thienyl group Chemical group 0.000 claims 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000002950 monocyclic group Chemical group 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims 4
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 208000007101 Muscle Cramp Diseases 0.000 claims 2
- 206010036018 Pollakiuria Diseases 0.000 claims 2
- 208000005392 Spasm Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- STTGOFBGRUQUOE-NDEPHWFRSA-N 2-[(4-chlorophenyl)methoxy]ethyl-[[2-[(r)-cyclohexyl-hydroxy-phenylmethyl]-1,3-oxazol-5-yl]methyl]-dimethylazanium Chemical group C=1N=C([C@@](O)(C2CCCCC2)C=2C=CC=CC=2)OC=1C[N+](C)(C)CCOCC1=CC=C(Cl)C=C1 STTGOFBGRUQUOE-NDEPHWFRSA-N 0.000 claims 1
- 229940121786 Beta 2 adrenoreceptor agonist Drugs 0.000 claims 1
- 206010048994 Bladder spasm Diseases 0.000 claims 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010063057 Cystitis noninfective Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010040741 Sinus bradycardia Diseases 0.000 claims 1
- 208000026723 Urinary tract disease Diseases 0.000 claims 1
- VJBGZNZVTFLMFK-NDEPHWFRSA-N [2-[(r)-cyclohexyl-hydroxy-phenylmethyl]-1,3-oxazol-5-yl]methyl-[2-[(3,4-dichlorophenyl)methoxy]ethyl]-dimethylazanium Chemical class C=1N=C([C@@](O)(C2CCCCC2)C=2C=CC=CC=2)OC=1C[N+](C)(C)CCOCC1=CC=C(Cl)C(Cl)=C1 VJBGZNZVTFLMFK-NDEPHWFRSA-N 0.000 claims 1
- GMCDICDKCSOMMG-NDEPHWFRSA-N [2-[(r)-cyclohexyl-hydroxy-phenylmethyl]-1,3-oxazol-5-yl]methyl-[3-(3,4-dichlorophenoxy)propyl]-dimethylazanium Chemical class C=1N=C([C@@](O)(C2CCCCC2)C=2C=CC=CC=2)OC=1C[N+](C)(C)CCCOC1=CC=C(Cl)C(Cl)=C1 GMCDICDKCSOMMG-NDEPHWFRSA-N 0.000 claims 1
- DFPAYMULYVSXEO-NDEPHWFRSA-N [2-[(r)-cyclohexyl-hydroxy-phenylmethyl]-1,3-oxazol-5-yl]methyl-dimethyl-(3-phenoxypropyl)azanium Chemical group C=1N=C([C@@](O)(C2CCCCC2)C=2C=CC=CC=2)OC=1C[N+](C)(C)CCCOC1=CC=CC=C1 DFPAYMULYVSXEO-NDEPHWFRSA-N 0.000 claims 1
- HYHKAXYXQQBGSC-LJAQVGFWSA-N [2-[(r)-cyclohexyl-hydroxy-phenylmethyl]-1,3-oxazol-5-yl]methyl-dimethyl-[2-(2-phenylethoxy)ethyl]azanium Chemical group C=1N=C([C@@](O)(C2CCCCC2)C=2C=CC=CC=2)OC=1C[N+](C)(C)CCOCCC1=CC=CC=C1 HYHKAXYXQQBGSC-LJAQVGFWSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 claims 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 claims 1
- 208000029162 bladder disease Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 201000003139 chronic cystitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229940124581 decongestants Drugs 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 201000003152 motion sickness Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 206010029446 nocturia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 102000017925 CHRM3 Human genes 0.000 abstract 1
- 101150060249 CHRM3 gene Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0516313.4A GB0516313D0 (en) | 2005-08-08 | 2005-08-08 | Azole derivatives and their uses |
| PCT/GB2006/002956 WO2007017669A1 (en) | 2005-08-08 | 2006-08-08 | Azole and thiazole derivatives and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100713T1 true HRP20100713T1 (hr) | 2011-01-31 |
Family
ID=34984297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100713T HRP20100713T1 (hr) | 2005-08-08 | 2010-12-21 | Derivati azola i tiazola i njihova upotreba |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20100113540A1 (pl) |
| EP (2) | EP1924570B1 (pl) |
| JP (1) | JP5047175B2 (pl) |
| KR (1) | KR20080046179A (pl) |
| CN (1) | CN101282949B (pl) |
| AT (1) | ATE485282T1 (pl) |
| AU (1) | AU2006277768B2 (pl) |
| BR (1) | BRPI0614291A2 (pl) |
| CA (1) | CA2617964A1 (pl) |
| CY (1) | CY1111720T1 (pl) |
| DE (1) | DE602006017715D1 (pl) |
| DK (1) | DK1924570T3 (pl) |
| EC (1) | ECSP088253A (pl) |
| ES (1) | ES2352755T3 (pl) |
| GB (1) | GB0516313D0 (pl) |
| HK (1) | HK1117147A1 (pl) |
| HR (1) | HRP20100713T1 (pl) |
| IL (1) | IL189267A (pl) |
| NO (1) | NO20081214L (pl) |
| NZ (1) | NZ566069A (pl) |
| PL (1) | PL1924570T3 (pl) |
| PT (1) | PT1924570E (pl) |
| RS (1) | RS51547B (pl) |
| RU (1) | RU2436779C2 (pl) |
| SI (1) | SI1924570T1 (pl) |
| UA (1) | UA95255C2 (pl) |
| WO (1) | WO2007017669A1 (pl) |
| ZA (1) | ZA200801603B (pl) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010501533A (ja) * | 2006-08-21 | 2010-01-21 | アージェンタ ディスカバリー リミテッド | Ｍ３レセプター調節物質として有用な窒素含有複素環化合物 |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| WO2008096093A1 (en) * | 2007-02-06 | 2008-08-14 | Argenta Discovery Ltd. | Oxazole and thiazole derivatives and their uses |
| GB0702414D0 (en) * | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | Oxazole and thiazole derivatives and their uses 2 |
| GB0702382D0 (en) * | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New salt |
| GB0702416D0 (en) * | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New combination |
| GB0702385D0 (en) * | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New combination |
| WO2008096129A1 (en) * | 2007-02-07 | 2008-08-14 | Argenta Discovery Ltd | Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors |
| JP5373634B2 (ja) * | 2007-02-07 | 2013-12-18 | パルメイゲン・セラピューティクス・（シナジー）・リミテッド | ムスカリンｍ３アンタゴニストのナパジシル酸塩 |
| US20100056565A1 (en) * | 2007-02-15 | 2010-03-04 | Argenta Discovery Limited | Heterocyclic Derivatives as M3 Muscarinic Receptors |
| WO2008103125A1 (en) * | 2007-02-23 | 2008-08-28 | Astrazeneca Ab | Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma |
| EP2146957B1 (en) | 2007-04-24 | 2013-06-12 | Theravance, Inc. | Quaternary ammonium compounds useful as muscarinic receptor antagonists |
| WO2008149110A1 (en) * | 2007-06-08 | 2008-12-11 | Argenta Discovery Limited | Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated |
| CN101796026B (zh) | 2007-09-07 | 2013-10-23 | 施万制药 | 可用作毒蕈碱受体拮抗剂的含胍化合物 |
| EP2222637A1 (en) | 2007-12-14 | 2010-09-01 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
| WO2009098453A1 (en) * | 2008-02-06 | 2009-08-13 | Astrazeneca Ab | Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists |
| WO2009098455A1 (en) * | 2008-02-06 | 2009-08-13 | Astrazeneca Ab | 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease |
| AU2008356409B2 (en) | 2008-05-13 | 2012-01-19 | Astrazeneca Ab | Quinuclidine derivatives as muscarinic M3 receptor antagonists |
| US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
| WO2010008341A1 (en) * | 2008-07-16 | 2010-01-21 | Astrazeneca Ab | A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist |
| WO2010015792A1 (en) * | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| WO2010018352A1 (en) * | 2008-08-12 | 2010-02-18 | Argenta Discovery Limited | Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| WO2011081937A1 (en) | 2009-12-15 | 2011-07-07 | Gilead Sciences, Inc. | Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy |
| EP3066072B1 (en) | 2013-11-07 | 2021-11-03 | The University of Kansas | Biphenylamide derivative hsp90 inhibitors |
| CA2959290A1 (en) * | 2014-08-26 | 2016-03-03 | Astellas Pharma Inc. | 2-aminothiazole derivative or salt thereof |
| TWI703138B (zh) * | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| AU2021236130A1 (en) * | 2020-03-11 | 2022-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| WO2022221071A1 (en) * | 2021-04-16 | 2022-10-20 | Ads Therapeutics Llc | Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307141B1 (en) * | 1987-09-10 | 1993-01-13 | MERCK SHARP & DOHME LTD. | Oxazoles and thiazoles for the treatment of senile dementia |
| IL88846A0 (en) * | 1988-01-08 | 1989-07-31 | Merck Sharp & Dohme | Lipophilic oxadiazoles,their preparation and pharmaceutical compositions containing them |
| GB2214180A (en) | 1988-01-12 | 1989-08-31 | Shell Int Research | Pytotoxic pyrrole-3,4-dicarboxylate derivatives |
| US5185354A (en) * | 1990-06-18 | 1993-02-09 | Mitsubishi Kasei Corporation | Pyrazolecarboxamide, insecticidal and miticidal composition, and fungicidal composition for use in agriculture and horticulture |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| JPH0525045A (ja) | 1991-07-18 | 1993-02-02 | Tanabe Seiyaku Co Ltd | 経皮吸収製剤 |
| WO1993018007A1 (en) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Novel carbostyril derivative |
| GB9603755D0 (en) * | 1996-02-22 | 1996-04-24 | Pfizer Ltd | Therapeutic agents |
| DK1273572T3 (da) * | 1997-10-09 | 2005-03-29 | Ortho Mcneil Pharm Inc | Thiophensubstituerede piperaziner anvendelige til behandling af binign prostatisk hyperplasi |
| US6057340A (en) * | 1998-02-03 | 2000-05-02 | American Home Products Corporation | Oxazole derivatives as serotonin-1A receptor agonists |
| JP2002501920A (ja) * | 1998-02-03 | 2002-01-22 | アメリカン・ホーム・プロダクツ・コーポレイション | セロトニン−１ａ受容体作動薬としてのオキサゾール誘導体 |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6242448B1 (en) * | 1998-12-17 | 2001-06-05 | American Home Products Corporation | Trisubstituted-oxazole derivatives as serotonin ligands |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| HUP0300832A2 (hu) | 2000-04-27 | 2003-08-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| US20020052312A1 (en) * | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| ES2292604T5 (es) | 2000-08-05 | 2015-06-01 | Glaxo Group Limited | Éster S-fluorometílico del ácido 6 ,9 -difluoro-17 -[(2-furanilcarbonil)oxi]-11 -hidroxi-16 -metil-3-oxo-androsta-1,4-dien-17 -carbotioico como agente antiinflamatorio |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| DE10104370A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Arzneimittelkompositionen mit geringeren Nebenwirkungen |
| DE10104367A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| DE60224172T2 (de) | 2001-03-22 | 2008-12-04 | Glaxo Group Ltd., Greenford | Formanilid-derivative als beta2-adrenorezeptor-agonisten |
| CN1302007C (zh) | 2001-04-30 | 2007-02-28 | 葛兰素集团有限公司 | 具有抗炎性的在17.α位上具有环酯基的雄甾烷的17.β.－硫代羧酸酯衍生物 |
| ATE399174T1 (de) | 2001-06-12 | 2008-07-15 | Glaxo Group Ltd | Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen |
| KR100912324B1 (ko) | 2001-09-14 | 2009-08-14 | 글락소 그룹 리미티드 | 호흡기 질환 치료용 펜에탄올아민 유도체 |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| AU2002356759A1 (en) | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
| WO2003053930A1 (en) | 2001-12-20 | 2003-07-03 | Bayer Healthcare Ag | 1,4-dihydro-1,4-diphenylpyridine derivatives |
| AU2003202044A1 (en) | 2002-01-15 | 2003-09-09 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
| WO2003062259A2 (en) | 2002-01-21 | 2003-07-31 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| PT1497289E (pt) | 2002-04-12 | 2005-11-30 | Boehringer Ingelheim Pharma | Farmaco contendo betamimeticos e um novo anticolinergico |
| ES2298511T3 (es) | 2002-04-25 | 2008-05-16 | Glaxo Group Limited | Derivados de fenetanolamina. |
| WO2003099764A1 (en) | 2002-05-28 | 2003-12-04 | Theravance, Inc. | ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| PE20050130A1 (es) | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
| GB0219896D0 (en) | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
| AU2003293356A1 (en) | 2002-08-27 | 2004-03-19 | Bayer Healthcare Ag | Dihydropyridinone derivatives as hne inhibitors |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| CA2498052C (en) | 2002-09-10 | 2011-05-17 | Bayer Healthcare Ag | Heterocyclic derivatives |
| AU2003282006C1 (en) | 2002-09-10 | 2009-11-26 | Bayer Schering Pharma Aktiengesellschaft | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory ischaemic and remodelling processes |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| AP2005003283A0 (en) | 2002-10-11 | 2005-06-30 | Pfizer | Indole derivatives useful for the treatment os diseases |
| EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
| ES2291733T3 (es) | 2002-10-22 | 2008-03-01 | Glaxo Group Limited | Compuestos de ariletanolamina medicinales. |
| PL377122A1 (pl) | 2002-10-28 | 2006-01-23 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| JP2004161702A (ja) | 2002-11-14 | 2004-06-10 | Hokko Chem Ind Co Ltd | γ−ジャスモラクトンの製造方法 |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| DE10258695A1 (de) | 2002-12-16 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neuer, langwirksamer Beta-agonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel |
| AU2004207482B2 (en) | 2003-01-21 | 2009-10-08 | Merck Sharp & Dohme Corp. | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
| GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| JP4767842B2 (ja) | 2003-04-01 | 2011-09-07 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物 |
| EP1613315B1 (en) | 2003-04-04 | 2009-01-21 | Novartis AG | Quinoline-2-one-derivatives for the treatment of airways diseases |
| US7268147B2 (en) | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
| EP1477167A1 (en) | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
| DE10323966A1 (de) | 2003-05-27 | 2004-12-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
| US7358244B2 (en) | 2003-05-28 | 2008-04-15 | Theravance, Inc. | Azabicycloalkane compounds |
| GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| MXPA05013059A (es) | 2003-06-04 | 2006-03-02 | Pfizer | Derivados de 2-amino-piridina como agonistas del adrenoceptor beta-2. |
| TW200510298A (en) | 2003-06-13 | 2005-03-16 | Theravance Inc | Substituted pyrrolidine and related compounds |
| US20050025718A1 (en) * | 2003-07-31 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| SE0302323D0 (sv) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302324D0 (sv) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| WO2005033121A2 (en) | 2003-10-03 | 2005-04-14 | King Pharmaceuticals Research & Development, Inc. | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs |
| GB0323701D0 (en) | 2003-10-09 | 2003-11-12 | Glaxo Group Ltd | Formulations |
| GB0324654D0 (en) | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0328490D0 (en) | 2003-12-09 | 2004-01-14 | Glaxo Group Ltd | Medicinal compounds |
| GB0329182D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
| US7648625B2 (en) | 2003-12-19 | 2010-01-19 | Shell Oil Company | Systems, methods, and catalysts for producing a crude product |
| DE102004001413A1 (de) | 2004-01-09 | 2005-08-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| EA011167B1 (ru) | 2004-01-22 | 2009-02-27 | Пфайзер Инк. | Производные сульфонамида для лечения заболеваний |
| JP4036343B2 (ja) | 2004-01-22 | 2008-01-23 | ファイザー・インク | 疾患の治療のためのスルフォンアミド誘導体 |
| DE102004003428A1 (de) | 2004-01-23 | 2005-08-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel |
| ES2349470T3 (es) | 2004-02-14 | 2011-01-03 | Boehringer Ingelheim International Gmbh | Nuevos beta-2-agonistas de acción de larga duración y su utilización como medicamentos. |
| ATE516285T1 (de) | 2004-02-19 | 2011-07-15 | Bayer Schering Pharma Ag | Dihydropyridinonderivate |
| ES2428503T3 (es) | 2004-02-26 | 2013-11-08 | Bayer Intellectual Property Gmbh | 1,4-Diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos |
| ES2394177T3 (es) | 2004-02-26 | 2013-01-23 | Bayer Intellectual Property Gmbh | 1,4-diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| EP1577306A1 (de) | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| EP1577292A1 (en) | 2004-03-17 | 2005-09-21 | Pfizer Limited | Phenylaminoethanol derivatives as beta2 receptor agonists |
| HN2004000023A (es) | 2004-03-22 | 2007-11-23 | Mars Inc | Mascadura para animales |
| WO2005092860A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds for the treatment of diseases |
| PL1730103T3 (pl) | 2004-03-23 | 2010-10-29 | Pfizer | Pochodne formamidu użyteczne jako adrenoreceptor |
| WO2005092841A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
| WO2005092887A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds for the treatment of diseases |
| EP1595873A1 (de) | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen |
| JP2007537187A (ja) | 2004-05-13 | 2007-12-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物 |
| DE102004024454A1 (de) | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004024453A1 (de) | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
| DE102004024451A1 (de) | 2004-05-14 | 2005-12-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten |
| US20080039495A1 (en) | 2004-06-03 | 2008-02-14 | Linsell Martin S | Diamine Beta2 Adrenergic Receptor Agonists |
| TW200540154A (en) | 2004-06-10 | 2005-12-16 | Theravance Inc | Crystalline form of a substituted pyrrolidine compound |
| EP1778638A1 (en) | 2004-07-21 | 2007-05-02 | Theravance, Inc. | Diaryl ether beta2 adrenergic receptor agonists |
| WO2006016245A1 (en) | 2004-08-05 | 2006-02-16 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| EP1778626A1 (en) | 2004-08-16 | 2007-05-02 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| JP2008510015A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| US7566785B2 (en) | 2004-09-10 | 2009-07-28 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
| DE102004045648A1 (de) | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| WO2006051373A1 (en) | 2004-11-12 | 2006-05-18 | Pfizer Limited | Compounds for the treatment of diseases |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| JP5373634B2 (ja) * | 2007-02-07 | 2013-12-18 | パルメイゲン・セラピューティクス・（シナジー）・リミテッド | ムスカリンｍ３アンタゴニストのナパジシル酸塩 |
| GB0702385D0 (en) * | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New combination |
-
2005
- 2005-08-08 GB GBGB0516313.4A patent/GB0516313D0/en not_active Ceased
-
2006
- 2006-08-08 AT AT06765253T patent/ATE485282T1/de active
- 2006-08-08 CN CN200680037447XA patent/CN101282949B/zh not_active Expired - Fee Related
- 2006-08-08 PT PT06765253T patent/PT1924570E/pt unknown
- 2006-08-08 ES ES06765253T patent/ES2352755T3/es active Active
- 2006-08-08 UA UAA200802945A patent/UA95255C2/ru unknown
- 2006-08-08 DE DE602006017715T patent/DE602006017715D1/de active Active
- 2006-08-08 WO PCT/GB2006/002956 patent/WO2007017669A1/en active Application Filing
- 2006-08-08 DK DK06765253.7T patent/DK1924570T3/da active
- 2006-08-08 US US12/063,216 patent/US20100113540A1/en not_active Abandoned
- 2006-08-08 EP EP06765253A patent/EP1924570B1/en active Active
- 2006-08-08 PL PL06765253T patent/PL1924570T3/pl unknown
- 2006-08-08 CA CA002617964A patent/CA2617964A1/en not_active Abandoned
- 2006-08-08 RU RU2008109023/04A patent/RU2436779C2/ru not_active IP Right Cessation
- 2006-08-08 JP JP2008525626A patent/JP5047175B2/ja not_active Expired - Fee Related
- 2006-08-08 RS RSP-2010/0563A patent/RS51547B/en unknown
- 2006-08-08 SI SI200630862T patent/SI1924570T1/sl unknown
- 2006-08-08 BR BRPI0614291-5A patent/BRPI0614291A2/pt not_active IP Right Cessation
- 2006-08-08 NZ NZ566069A patent/NZ566069A/en not_active IP Right Cessation
- 2006-08-08 KR KR1020087005725A patent/KR20080046179A/ko active IP Right Grant
- 2006-08-08 EP EP10170818A patent/EP2280006A1/en not_active Withdrawn
- 2006-08-08 AU AU2006277768A patent/AU2006277768B2/en not_active Ceased
-
2008
- 2008-02-04 IL IL189267A patent/IL189267A/en not_active IP Right Cessation
- 2008-02-18 ZA ZA200801603A patent/ZA200801603B/xx unknown
- 2008-03-07 EC EC2008008253A patent/ECSP088253A/es unknown
- 2008-03-07 NO NO20081214A patent/NO20081214L/no not_active Application Discontinuation
- 2008-07-07 HK HK08107404.7A patent/HK1117147A1/xx not_active IP Right Cessation
-
2010
- 2010-12-16 CY CY20101101158T patent/CY1111720T1/el unknown
- 2010-12-21 HR HR20100713T patent/HRP20100713T1/hr unknown
-
2012
- 2012-04-24 US US13/454,159 patent/US20120277275A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100713T1 (hr) | Derivati azola i tiazola i njihova upotreba | |
| KR100659007B1 (ko) | 아미드 화합물 및 그 의약으로서의 용도 | |
| JP4696069B2 (ja) | Ｎ−［ヘテロアリル（ピペリジン−２−イル）メチル］ベンズアミドの誘導体、この調製方法およびこの治療法における使用 | |
| RU2008108996A (ru) | Производные бицикло[2, 2, 1]гепт-7-иламина и их применения | |
| AU2006228413C1 (en) | Treatment of Parkinson's Disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands | |
| US7244758B2 (en) | N-type calcium channel blockers | |
| CA2624361A1 (en) | Methods of using small molecule compounds for neuroprotection | |
| CA2563674A1 (en) | .alpha.-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders | |
| RU2008125433A (ru) | (r)-арилалкиламинопроизводные и содержащие их фармацевтические композиции | |
| US7507760B2 (en) | N-type calcium channel blockers | |
| NO20071058L (no) | Risedronatsammensetninger og deres fremgangsmater for anvendelse | |
| JP2009501775A (ja) | 癌治療におけるチアゾール誘導体およびアナログの使用 | |
| RU2010138577A (ru) | ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3 | |
| RU2011105813A (ru) | Азотсодержащие гетероциклические соединения | |
| NO20054214L (no) | Iminoeterderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel | |
| RU2009133258A (ru) | Гетероциклические производные в качестве ингибиторов мускариновых рецепторов типа мз | |
| US20220106292A1 (en) | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use | |
| EP2155183A1 (en) | Amino acid derivatives as calcium channel blockers | |
| HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
| CA2603683A1 (en) | Treatment of epilepsy with non-imidazole alkylamines histamine h3-receptor ligands | |
| JP2007531755A (ja) | 非イミダゾール系複素環式化合物 | |
| JP2007501270A5 (pl) | ||
| HRP20090647T1 (hr) | Novi derivati 3-fenilpropionske kiseline i nihova uporaba kao ppar-gama receptorskih liganada | |
| JP6979968B2 (ja) | 環縮合チアゾリノ２−ピリドン類、その製造方法並びに結核の処置及び／又は予防におけるそれらの使用 | |
| US20100029681A1 (en) | Heterocyclic compounds as calcium channel blockers |